Coming soon.

The IDR Spring Conference titled “Targeting Drug Resistance” is available for download here.

Over 100 participants from academia, industry, policy development organizations and government assembled on May 16, 2011 to continue the cross disciplinary discussions and investigations into the parallels by which drug resistance arise in quickly evolving diseases. Speakers included: Dr. Marie-Pierre de Bethune, Vice President of External Innovation at Tibotec/Johnson & Johnson; Stephen Becker, MD, Senior Program Officer, Infectious Diseases Development, Gates Foundation; Dr. Stephen Hughes, Director, HIV Drug Resistance Program, Chief, Retroviral Replication Laboratory; and Head, Vector Design and Replication Section, National Cancer Institute; Dr. Nathanael Gray, Assistant Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Dr. Sarah Fortune, Assistant Professor of Immunology and Infectious Diseases, Harvard School of Public Health; and Ms. Sharon Ladin, Director, Antibiotics and Innovation Project, The Pew Charitable Trusts. “Advocating for Policies that Prime the Antibiotics Pipeline.

The IDR’s first conference titled “Changing the Paradigms of Drug Resistance” is available for download here.

113 researchers, clinicians, industry representatives and graduate students attended this first all day conference which took place on October 4, 2010. Speakers included Dr. Stuart Levy, MD, Professor of Molecular Biology & Microbiology and of Medicine at Tufts University School of Medicine; Director of the Center for Adaptation Genetics and Drug Resistance; President of the Alliance for the Prudent Use of Antibiotics, Dr. Sally Blower, PhD, Professor and Head of Disease Modeling Group, Semel Institute of Neuroscience & Human Behavior, Geffen School of Medicine at UCLA, Dr. James Collins, PhD, Howard Hughes Medical Institute, Professor of Biomedical Engineering, Boston University & Wyss Institute for Biologically Inspired Engineering, Harvard University, as well as other notable researchers representing multiple approaches to a common focus of how best to deal with the challenge of drug resistance.

The IDR's second workshop titled: "Approaches and Technologies to Avoid Drug Resistance"is available for download here . Attended by over 40 research scientists, clinicians, and industry representatives the workshop focused on approaches and technologies commonly used by drug researchers in an effort to explore the parallels in use between different disease states. Dr. Daia Hazuda, Vice President, Worldwide Discovery at Merck Research Laboratories spoke about HCV antiviral drug resistance, specifically addressing lessons and opportunities from this work, as well as parallels with HIV research. Roy Kishony, PhD., Associate Professor of Systems Biology at Harvard Medical School addressed the topic of inverting selection for antibiotic resistance through the use of suppressive drug combinations.